The Bill That Outlives the Illness
In the United States, healthcare affordability and medical debt remain structurally embedded in the delivery system, not aberrations at its ...
When Authority Fractures
Health misinformation has become less a discrete problem than a structural feature of the digital environment. Social platforms distribute medical ...
The Second Brain Goes Viral
The gut-brain axis—once a niche topic in neurogastroenterology and mucosal immunology—is now a staple of TikTok explainers and supplement ...
The Calendar Becomes Capital
The United States fertility rate has declined to historic lows, falling below replacement level for more than a decade. According ...
Hospital Pharmacies: Designing for Zero Errors
Here’s how smart layout and storage choices in hospital pharmacies reduce mix-ups, streamline workflow, and support safer dispensing without adding ...
When the Dose Is a Guess
The opioid crisis in the United States has entered a synthetic phase defined less by prescription volume than by the ...
When Prognosis Becomes Probabilistic
Cancer immunotherapy and mRNA-based oncology platforms have not abolished mortality, but they have unsettled its predictability. Immune checkpoint inhibitors targeting ...
When the Scalpel Depends on Scarcity
Antibiotics transformed once-lethal procedures into routine interventions. Cesarean delivery, joint replacement, appendectomy—each depends not merely on technical precision but on ...
When the Algorithm Is Right
Artificial intelligence systems trained on large-scale imaging and clinical datasets now rival, and in some narrow domains exceed, human diagnostic ...
When Attention Becomes a Diagnosis
Attention-deficit/hyperactivity disorder has moved from the margins of pediatric psychiatry into the center of educational policy and pharmaceutical logistics. Over ...
Rewiring the Degenerating Brain
In recent weeks, Parkinson’s disease has returned to the center of scientific and policy discourse as early-phase clinical trials implant ...
The Quiet Surge in the Mind’s Marketplace
Behavioral health utilization in the United States has climbed steadily over the past several years, with particularly sharp increases in ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more